Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 6

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

Authors Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Published Date January 2007 Volume 2007:3(6) Pages 967—973

DOI http://dx.doi.org/

Published 15 January 2007

Behzad Molavi1, Negah Rassouli2, Suveer Bagwe1, Neda Rasouli2

Central Arkansas Veterans Healthcare System and University of Arkansas for Medical sciences, 1Division of cardiology and 2Division of Endocrinology, College of Medicine, Little Rock, Arkansas, USA

Abstract: The rising incidence of obesity and insulin resistance to epidemic proportions has closely paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic inflammation as the common denominators in the evolution of insulin resistance and diabetes. Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone and metformin have been shown to exert anti-oxidative and anti-inflammatory effects in vascular beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of morbidity and mortality in the affected population. The combination of pioglitazone and metformin would thus appear to be an effective pharmacological intervention in prevention and treatment of diabetes. Finally, this review will address the currently available evidence on diabetic cardiomyopathy and the potential role of combination therapy with pioglitazone and metformin.

Keywords: insulin resistance, oxidative stress, inflammation, pioglitazone, metformin, atherosclerosis, diabetic cardiomyopathy

Download Article [PDF] 

Readers of this article also read:

Anabolic steroids, acute myocardial infarction and polycythemia: A case report and review of the literature

Kathleen Stergiopoulos, Joseph J Brennan, Robin Mathews, John F Setaro, Smadar Kort

Vascular Health and Risk Management 2008, 4:1475-1480

Published Date: 20 November 2008

Characterizing blood microparticles: Technical aspects and challenges

Arun S Shet

Vascular Health and Risk Management 2008, 4:769-774

Published Date: 4 September 2008

Gadofosveset-enhanced magnetic resonance angiography

Mathias Goyen

Vascular Health and Risk Management 2008, 4:1-9

Published Date: 5 March 2008

Cholesterol lowering for secondary prevention: What statin dose should we use?

Kiranbir Josan, Finlay A McAlister

Vascular Health and Risk Management 2007, 3:615-627

Published Date: 20 November 2007

Update on stents: Recent studies on the TAXUS® stent system in small vessels

Shuzou Tanimoto, Joost Daemen, Patrick W Serruys

Vascular Health and Risk Management 2007, 3:481-490

Published Date: 4 October 2007

Sirolimus-eluting coronary stents: a review

Alexandre Abizaid

Vascular Health and Risk Management 2007, 3:191-201

Published Date: 23 May 2007

Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity

Barbara Ludolph, Wilhelm Bloch, Malte Kelm, Rainer Schulz, Petra Kleinbongard

Vascular Health and Risk Management 2007, 3:1069-1073

Published Date: 15 January 2007

Management of cancer-associated venous thrombosis

Ozlem Er, Leo Zacharski

Vascular Health and Risk Management 2006, 2:351-356

Published Date: 1 March 2006

Screening for popliteal aneurysms should not be a routine part of a community-based aneurysm screening program

Martin Claridge, Simon Hobbs, Clive Quick, Donald Adam, Andrew Bradbury, Teun Wilmink

Vascular Health and Risk Management 2006, 2:189-191

Published Date: 25 January 2006